尿路系癌市場：現状分析および予測（2022年～2028年）

世界の尿路系癌の市場規模は、予測期間中に約18％の成長率で拡大すると予測されています。膀胱癌の発生率の増加、研究センター建設のための民間および公的資金の増加、高齢者人口の増加、ヘルスケア産業における研究開発活動の増加によって同市場の促進が促進されています。

当レポートは、世界の尿路系癌市場について調査し、市場の概要とともに、癌タイプ別、治療タイプ別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場イントロダクション

第2章 調査方法または仮定

第3章 市場要約

第4章 エグゼクティブサマリー

第5章 COVID-19が尿路系癌市場に与える影響

第6章 尿路系癌市場の収益、2020-2028F

第7章 癌タイプ別の市場洞察

• 膀胱癌
• 尿道癌
• 尿管癌および腎盂癌

第8章 治療タイプ別の市場洞察

• 化学療法
• 免疫療法

第9章 流通チャネル別の市場洞察

• 小売薬局
• オンライン薬局

第10章 地域別の市場洞察

• 北米
• 欧州
• アジア太平洋
• その他の地域

第11章 尿路系癌市場の市場力学

• 市場促進要因
• 市場の課題
• 影響分析

第12章 尿路系癌の市場機会

第13章 尿路系癌市場の動向

第14章 需要側と供給側の分析

第15章 バリューチェーン分析

第16章 競合シナリオ

第17章 企業プロファイル

• F. Hoffmann-La Roche
• AstraZeneca plc
• Bristol-Myers Squibb
• Merck & Co Inc.
• Johnson & Johnson
• Eli Lilly and Co.
• GlaxoSmithKline plc
• Novartis International AG
• Pfizer Inc.
• Astellas Pharma Inc.

第18章 免責事項

The global urinary tract cancer market is expected to grow at a significant rate of around 18% during the forecast period. Urinary tract cancer is a type of cancer that affects the urethra, bladder, and renal pelvic. In the therapeutic treatment of various types of cancers related to the urinary tract, including bladder cancer, ureteric cancer, renal pelvic cancer, and urethral cancer, the solutions provided by pharmaceutical players and manufacturers in the global urinary tract cancer market are utilized.

The global urinary tract cancer market is being propelled forward by an increase in the incidence of bladder cancer, an increase in private and public funding for the construction of research centers, an increase in the elderly population, and an increase in research and development activities in the healthcare industry. The tenth most common type of cancer worldwide is bladder cancer. For instance, in 2021, approximately 83,730 Americans were diagnosed with bladder cancer, according to the American Cancer Society.

F. Hoffmann-La Roche, AstraZeneca plc, Bristol-Myers Squibb, Merck & Co Inc., Johnson & Johnson, Eli Lilly and Co., GlaxoSmithKline plc, Novartis International AG, Pfizer Inc., Sanofi, and Astellas Pharma Inc. are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst treatment type, immunotherapy category to witness robust CAGR during the forecast period"

Based on treatment type, the market is segmented into chemotherapy and immunotherapy. Among them, the chemotherapy category is to witness a higher CAGR during the forecast period. Chemotherapy may help relieve signs and symptoms of cancer by killing some of the cancer cells. In addition, clinical trials have shown that patients with invasive bladder cancer who receive intravenous chemotherapy prior to a radical cystectomy have a better chance of survival. For instance, according to the American Cancer Society, in the United States, there are estimated to be 829,620 survivors of urinary bladder cancer, and an additional 80,470 cases were diagnosed in 2019 and more than 70% of patients with bladder cancer are diagnosed with non-muscle-invasive disease.

"Amongst distribution channel, the retail pharmacy to hold a significant share in the market in 2020"

On the basis of distribution channel, the market is categorized into the retail pharmacy and online pharmacy. Among these, retail pharmacy to hold a significant share of the market in 2020. This is mainly due to the rise in the prevalence of cancer, the surge in demand for the prescribed drug, and the increase in the drug approved for the treatment of cancer. However, the online pharmacy segment is also witnessing significant growth during the forecast period owing to the growing demand for monitoring services and advancements in the technology in the medical sector

"North America to hold a significant share in the market"

For a better understanding of the market adoption of the urinary tract cancer treatment industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the growing healthcare spending in the region, an increase in the prevalence of bladder cancer, the presence of numerous well-established industry players, and the availability of cutting-edge and strong cancer treatment solutions in regional healthcare infrastructures and facilities are the major key factor which will boost the growth of the market during the forecast period.

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

The report presents a quick review of overall industry performance at one glance.

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

The study comprehensively covers the market across different segments.

Deep dive regional level analysis of the industry.

Customization Options:

The global urinary tract cancer market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Urinary Tract Cancer Market
• 2.2. Research Methodology of the Urinary Tract Cancer Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE URINARY TRACT CANCER MARKET

6 URINARY TRACT CANCER MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY CANCER TYPE

• 7.1. Bladder Cancer
• 7.2. Urethral Cancer
• 7.3. Ureteric and Renal Pelvic Cancer

8 MARKET INSIGHTS BY TREATMENT TYPE

• 8.1. Chemotherapy
• 8.2. Immunotherapy

9 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 9.1. Retail Pharmacy
• 9.2. Online Pharmacy

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 URINARY TRACT CANCER MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 URINARY TRACT CANCER MARKET OPPORTUNITIES

13 URINARY TRACT CANCER MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1. F. Hoffmann-La Roche
• 17.2. AstraZeneca plc
• 17.3. Bristol-Myers Squibb
• 17.4. Merck & Co Inc.
• 17.5. Johnson & Johnson
• 17.6. Eli Lilly and Co.
• 17.7. GlaxoSmithKline plc
• 17.8. Novartis International AG
• 17.9. Pfizer Inc.
• 17.10. Astellas Pharma Inc.

18 DISCLAIMER